Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q2 FY2012 Earnings Presentation
8 slides from Alembic Pharmaceuticals's earnings presentation, September 2011
Slide 1: Investors Update – Q2FY12
Alembic Pharmaceuticals Limited Investors Update – Q2FY12 Net sales up 24% at Rs 398 crores against Rs. 321 crores in corresponding quarter last year Domestic formulations up 10% at Rs. 227 crores against Rs. 207 crores in corresponding quarter last year International Generics up by 79% to Rs.
Slide 2: Management Discussion – Q2FY11
Management Discussion – Q2FY11 Alembic Pharmaceuticals Limited, the pharmaceutical major, today reported a 24% increase in revenues to Rs 398.05 crores for the quarter ended 30th September 2011, compared to Rs 321.17 crores in the corresponding quarter last year. The Company posted an impressive 47%
Slide 3: Domestic branded business and International Generics
The company continues to make efforts in the domestic branded business, particularly with the newer specialty segments. Gastro, Cardio, Anti Diabetic, Gynaec and Opthal are growing at higher than respective market growth. The positive impact of the restructuring undertaken in the recent past is evid
Slide 4: API Business and regional sales
API Export Sales - Region w ise in % International Generics Sales - Regionwise in % 42% 38% 43% US/Canada 19% 58% Europe US / Canada Europe ROW API Business Domestic API sales grew 40% at Rs. 22.01 crores against Rs. 15.69 crores of PY. Export API sales grew 50% at Rs. 60.44 crores against Rs. 40.
Slide 5: Financial and Operating Result – Q2FY12
Export Sales Total Revenue 45000 16000 40000 Domestic Business 14000 Regulatory Sales 35000 Export Business 12000 ROW Sales R e v e n u e s in L a c s R e v e n u e in L a c s 30000 Total Total 10000 25000 8000 20000 6000 15000 10000 4000 5000 2000 0 0 Q2FY12 Q2FY11 Q2FY12 Q2FY11 Total Sales Q2FY12
Slide 6: Profit and loss statement Q2FY12
Particulars Rs. lacs Income from Operations 39799 Total Expenditure 33752 - (Increase) / decrease in stock (2085) - Consumption of Raw Material 15422 - Consumption of Traded Goods 6036 - Employee cost 3715 - Research and Development Expense 1309 - Excise Duty Exp 243 - Other expenditure 9112 Operati
Slide 7: Summary of total revenue (consolidated) for the quarter
Summary of total revenue (consolidated) for the quarter: (Rs. in Lacs) Particulars Q2 FY12 Q2 FY11 % Change Formulation Domestic 22692 20683 10% International Branded 1204 1495 (-)19% International Generics 7138 3979 79% API Domestic 2201 1569 40% International 6044 4041 50% Export incentives 526 35
Slide 8: About Alembic Pharmaceuticals Limited
About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market lea
Alembic Pharmaceuticals — Q2 FY2012 Earnings Presentation on 6ix